About Venclose
Venclose is a company based in San Jose (United States) founded in 2014 by Brady Esch was acquired by Becton Dickinson in December 2021. Venclose has raised $27.1 million across 2 funding rounds from investors including BD and Ally Bridge Group. Venclose offers products and services including Venclose RF Ablation System, Venclose RF Ablation Catheter, and Venclose Maven Perforator Catheter. Venclose operates in a competitive market with competitors including Monteris, Neo, TechsoMed, Symmetry Surgical and Misonix, among others.
- Headquarter San Jose, United States
- Founders Brady Esch
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Becton, Dickinson And Company
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$27.1 M (USD)
in 2 rounds
-
Latest Funding Round
$27.1 M (USD), Series C
Nov 27, 2019
-
Investors
BD
& 1 more
-
Employee Count
Not available
-
Acquired by
Becton Dickinson
(Dec 02, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Venclose
Venclose offers a comprehensive portfolio of products and services, including Venclose RF Ablation System, Venclose RF Ablation Catheter, and Venclose Maven Perforator Catheter.
System for endovascular coagulation of blood vessels in venous reflux.
Device for treating superficial vein reflux with radiofrequency.
Catheter for managing perforator and tributary vein reflux.
People of Venclose
Unlock access to complete
Unlock access to complete
Funding Insights of Venclose
Venclose has successfully raised a total of $27.1M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $27.1 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Venclose
Venclose has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BD and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
BD is recognized for providing innovative medical technology solutions.
|
Locked | Locked | Locked |
Investor details for Venclose
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Venclose
Investment portfolio details for Venclose
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Venclose
Detailed financials for Venclose
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Venclose Comparisons
Peer comparison for Venclose
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Venclose
Venclose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Monteris, Neo, TechsoMed, Symmetry Surgical and Misonix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
MRI-guided laser ablation tools for neurosurgery are developed.
|
|
| Locked | Locked | Locked |
Blockchain infrastructure is utilized for developing decentralized applications.
|
|
| Locked | Locked | Locked |
Ultrasound-based monitoring systems for thermal ablation procedures are developed.
|
|
| Locked | Locked | Locked |
Surgical instruments, sterilization solutions and electrosurgical products
|
|
| Locked | Locked | Locked |
Ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery
|
|
| Locked | Locked | Locked |
Surgical products for soft tissue cutting
|
Detailed competitors of Venclose
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Venclose
Complete news archive for Venclose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Venclose
Venclose was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Venclose is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Brady Esch is the current CEO of Venclose. They have also founded this company.
Venclose is a funded company, having raised a total of $27.1M across 2 funding rounds to date.
Venclose has developed a Radiofrequency (RF) ablation system for the treatment of venous reflux disease. The Venclose device consists fo two heating lengths and a catheter. The features are the instrument has markings, curved tip, minimizes invasiveness, shows real-time procedure data etc.
Venclose offers Venclose RF Ablation System, Venclose RF Ablation Catheter, and Venclose Maven Perforator Catheter.
Venclose has 2 investors. Key investors include BD, and Ally Bridge Group.